SIRPA and non-Hodgkin lymphoma: Here we report: (1) clinical safety, preliminary activity, and pharmacokinetics (PK) of GS‐0189 as monotherapy and combination therapy with rituximab, from a phase 1 first‐in‐human (FIH) clinical trial in patients with R/R NHL (NCT04502706); (2) in vitro characterization of GS‐0189 binding potency to SIRPα variants; (3) and in vitro phagocytic activity of macrophages derived from donors possessing different SIRPα variants relative to the activity of a control pan‐SIRP blocking antibody with an inert Fc, KWAR23.